Pfizer Inc. (PFE)
After hours:
| Previous Close | 27.77 |
| Open | 27.70 |
| Bid | 28.20 x 3100 |
| Ask | 28.14 x 3200 |
| Day's Range | 27.52 - 28.34 |
| 52 Week Range | 25.20 - 40.37 |
| Volume | |
| Avg. Volume | 42,456,437 |
| Market Cap | 160.08B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 1.68 (6.05%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 31.37 |
Investor's Business DailyPfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
- Reuters
UPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal. The agreements cover cases in U.S. state courts but don't completely resolve the company's exposure to Zantac claims, the report said, adding that financial details of the deals were not immediately available. Pfizer did not immediately respond to a Reuters request for comment.
